These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
6. The actions of SGLT2 inhibitors on metabolism, renal function and blood pressure. Thomas MC; Cherney DZI Diabetologia; 2018 Oct; 61(10):2098-2107. PubMed ID: 30132034 [TBL] [Abstract][Full Text] [Related]
7. The roles of sodium-glucose cotransporter 2 inhibitors in preventing kidney injury in diabetes. Jaikumkao K; Pongchaidecha A; Chatsudthipong V; Chattipakorn SC; Chattipakorn N; Lungkaphin A Biomed Pharmacother; 2017 Oct; 94():176-187. PubMed ID: 28759755 [TBL] [Abstract][Full Text] [Related]
8. Diabetic nephropathy: Renoprotective effects of GLP1R agonists and SGLT2 inhibitors. Hocher B; Tsuprykov O Nat Rev Nephrol; 2017 Dec; 13(12):728-730. PubMed ID: 28989173 [No Abstract] [Full Text] [Related]
9. Development of SGLT1 and SGLT2 inhibitors. Rieg T; Vallon V Diabetologia; 2018 Oct; 61(10):2079-2086. PubMed ID: 30132033 [TBL] [Abstract][Full Text] [Related]
10. Is the joint use of diuretics and SGLT2 inhibitors beneficial in diabetic kidney disease? León-Jiménez D; Moreno-Obregón F; Beltrán-Romero LM; Miramontes-González JP Kidney Int; 2020 Jan; 97(1):213. PubMed ID: 31901343 [No Abstract] [Full Text] [Related]
11. Glycemic control by the SGLT2 inhibitor empagliflozin decreases aortic stiffness, renal resistivity index and kidney injury. Aroor AR; Das NA; Carpenter AJ; Habibi J; Jia G; Ramirez-Perez FI; Martinez-Lemus L; Manrique-Acevedo CM; Hayden MR; Duta C; Nistala R; Mayoux E; Padilla J; Chandrasekar B; DeMarco VG Cardiovasc Diabetol; 2018 Jul; 17(1):108. PubMed ID: 30060748 [TBL] [Abstract][Full Text] [Related]
12. Effect of SGLT2 inhibitors on cardiovascular, renal and safety outcomes in patients with type 2 diabetes mellitus and chronic kidney disease: A systematic review and meta-analysis. Toyama T; Neuen BL; Jun M; Ohkuma T; Neal B; Jardine MJ; Heerspink HL; Wong MG; Ninomiya T; Wada T; Perkovic V Diabetes Obes Metab; 2019 May; 21(5):1237-1250. PubMed ID: 30697905 [TBL] [Abstract][Full Text] [Related]
13. Diabetic kidney disease in type 1 diabetes: challenges and differences from type 2 diabetes. Popovic DS; Patoulias D; Gnudi L; Mantzoros CS Metabolism; 2024 Feb; 151():155763. PubMed ID: 38122894 [No Abstract] [Full Text] [Related]
14. Renal sodium-dependent glucose cotransporter 2 (SGLT2) inhibitors for new anti-diabetic agent. Nomura S Curr Top Med Chem; 2010; 10(4):411-8. PubMed ID: 20180760 [TBL] [Abstract][Full Text] [Related]
16. Sodium/glucose cotransporter 2 inhibitors and prevention of diabetic nephropathy: targeting the renal tubule in diabetes. De Nicola L; Gabbai FB; Liberti ME; Sagliocca A; Conte G; Minutolo R Am J Kidney Dis; 2014 Jul; 64(1):16-24. PubMed ID: 24673844 [TBL] [Abstract][Full Text] [Related]
17. SGLT2 inhibitors for the prevention of kidney failure in patients with type 2 diabetes: a systematic review and meta-analysis. Neuen BL; Young T; Heerspink HJL; Neal B; Perkovic V; Billot L; Mahaffey KW; Charytan DM; Wheeler DC; Arnott C; Bompoint S; Levin A; Jardine MJ Lancet Diabetes Endocrinol; 2019 Nov; 7(11):845-854. PubMed ID: 31495651 [TBL] [Abstract][Full Text] [Related]
18. Mechanisms of Protective Effects of SGLT2 Inhibitors in Cardiovascular Disease and Renal Dysfunction. Liu B; Wang Y; Zhang Y; Yan B Curr Top Med Chem; 2019; 19(20):1818-1849. PubMed ID: 31456521 [TBL] [Abstract][Full Text] [Related]
19. Research digest: SGLT2 inhibition in kidney and liver disease. Preiss D; Sattar N Lancet Diabetes Endocrinol; 2019 Jun; 7(6):427. PubMed ID: 31103176 [No Abstract] [Full Text] [Related]
20. Do sodium-glucose co-transporter-2 inhibitors prevent heart failure with a preserved ejection fraction by counterbalancing the effects of leptin? A novel hypothesis. Packer M Diabetes Obes Metab; 2018 Jun; 20(6):1361-1366. PubMed ID: 29359851 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]